The Food and Drug Administration approves leucovorin for children and adults with cerebral folate deficiency while stopping short of endorsing the drug as a treatment for autism more broadly.The approval narrows a review launched after a White House news conference where Donald Trump and Marty Makary suggested wider autism benefits, statements agency officials later walked back after a supporting study was retracted.FDA says it will allow imports to ease shortages,
GlaxoSmithKline will not relaunch its branded version, and medical societies including the American Academy of Pediatrics say evidence remains inconclusive for routine autism use.